Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali 7-jild 2-son (2022)
THE EVALUATION OF THE EFFECTIVENESS AND SAFETY OF THE USE OF FIXED TRIPLE ORAL SUGAR-REDUCING THERAPY WITH DEBISTAL-GM IN PATIENTS WITH TYPE 2 DIABETES WITH OBESITY
РАХИМОВА Гулнара Нишановна, АХРОРОВ Камиль Убайдуллаевич
Annotatsiya
Given the complexity and versatility of the pathogenesis of type 2 diabetes, the choice of antihyperglycemic drugs is based on the importance of a simultaneous combined effect on several links in the pathogenesis of type 2 diabetes. The aim of the study was to study the hypoglycemic efficacy, clinical tolerance and safety of Debistal-GM in obese patients with type 2 diabetes. As a result of the study, high clinical efficacy, good tolerability and safety of Debistal-GM in obese type 2 diabetes were established. Inclusion criteria for the use of Debistal-GM are patients with type 2 diabetes with glycated hemoglobin values above 9%, but below 11%; with a diabetes duration of more than 5 years, with a body mass index of more than 30 kg / m 2.
сахарный диабет 2 типа, пиоглитазон, фиксированная комбинированная терапия СД 2 типа, трёхкомпонентная антигипер-гликемическая терапияtype 2 diabetes mellitus, pioglitazone, fixed combination therapy for type 2 diabetes, triple antihyperglycemic therapyқандли диабет 2-тур, пиоглитазон, ҚД 2-турнинг фиксацияланган комбинирланган давоси, уч таркибли антигипрегликемик даво
Metadata manbasi: jurnal OAI-PMH arxivi · Sindex toʻliq matnni saqlamaydi, manbaga havola beradi.